Related Experiment Video
Updated: Jun 20, 2025

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel PPARG
Liyuan Zhou1,2, Shunhua Li1, Jing Ren1
1Key Laboratory of Endocrinology of National Health Commission, Diabetes Research Center of Chinese Academy of Medical Sciences, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Abstract:
Familial partial lipodystrophy 3 (FPLD3) is a rare genetic disorder caused by loss-of-function mutations in the PPARG gene, characterized by a selective absence of subcutaneous fat and associated metabolic complications. However, the molecular mechanisms of FPLD3 remain unclear. In this study, we recruited a 17-yr-old Chinese female with FPLD3 and her family, identifying a novel PPARG frameshift mutation (exon 4: c.418dup: p.R140Kfs*7) that truncates the PPARγ protein at the seventh amino acid, significantly expanding the genetic landscape of FPLD3. By performing next-generation sequencing of circular RNAs (circRNAs), microRNAs (miRNAs), and mRNAs in plasma exosomes, we discovered 59 circRNAs, 57 miRNAs, and 299 mRNAs were significantly altered in the mutation carriers compared with the healthy controls. Integration analysis highlighted that the circ_0001597-miR-671-5p pair and 18 mRNAs might be incorporated into the metabolic regulatory networks of the FPLD3 induced by the novel PPARG mutation. Functional annotation suggested that these genes were significantly enriched in glucose- and lipid metabolism-related pathways. Among the circRNA-miRNA-mRNA network, we identified two critical regulators, early growth response-1 (EGR1), a key transcription factor known for its role in insulin signaling pathways and lipid metabolism, and 1-acylglycerol-3-phosphate O-acyltransferase 3 (AGPAT3), which gets involved in the biosynthesis of triglycerides and lipolysis. Circ_0001597 regulates the expression of these genes through miR-671-5p, potentially contributing to the pathophysiology of FPLD3. Overall, this study clarified a circulating exosomal circRNA-miRNA-mRNA network in a FPLD3 family with a novel PPARG mutation, providing evidence for exploring promising biomarkers and developing novel therapeutic strategies for this rare genetic disorder.NEW & NOTEWORTHY Through the establishment of a ceRNA regulatory networks in a novel PPARG frameshift mutation c.418dup-induced FPLD3 pedigree, this study reveals that circ_0001597 may contribute to the pathophysiology of FPLD3 by sequestering miR-671-5p to regulate the expression of EGR1 and AGPAT3, pivotal genes situated in the triglyceride (TG) synthesis and lipolysis pathways. Current findings expand our molecular understanding of adipose tissue dysfunction, providing potential blood biomarkers and therapeutic avenues for lipodystrophy and associated metabolic complications.
Insights
Familial partial lipodystrophy 3 (FPLD3) is linked to a novel PPARG mutation. A circRNA-miRNA-mRNA network in plasma exosomes reveals potential biomarkers and therapeutic targets for this rare genetic disorder.
Area of Science:
- Genetics and Molecular Biology
- Endocrinology and Metabolism
Background:
- Familial partial lipodystrophy 3 (FPLD3) is a rare genetic disorder caused by PPARG mutations, leading to fat absence and metabolic issues.
- The precise molecular mechanisms underlying FPLD3 pathogenesis remain incompletely understood.
Purpose of the Study:
- To identify a novel genetic mutation in FPLD3 and elucidate the molecular mechanisms involved.
- To investigate the role of circulating exosomal circRNA-miRNA-mRNA networks in FPLD3 pathophysiology.
Main Methods:
- Recruited a Chinese FPLD3 family and performed genetic sequencing to identify mutations.
- Utilized next-generation sequencing on plasma exosomes to analyze circRNAs, miRNAs, and mRNAs.
- Conducted integration analysis and functional annotation to identify key regulatory networks and genes.
Main Results:
- Identified a novel PPARG frameshift mutation (c.418dup: p.R140Kfs*7) in the FPLD3 patient.
- Discovered significant alterations in 59 circRNAs, 57 miRNAs, and 299 mRNAs in mutation carriers.
- Highlighted a circ_0001597-miR-671-5p-EGR1/AGPAT3 network involved in glucose and lipid metabolism.
Conclusions:
- The novel PPARG mutation contributes to FPLD3 by disrupting metabolic regulation via an exosomal circRNA-miRNA-mRNA network.
- Circ_0001597 may play a key role by sequestering miR-671-5p, affecting triglyceride synthesis and lipolysis through EGR1 and AGPAT3.
- Findings suggest potential blood-based biomarkers and novel therapeutic strategies for FPLD3 and related metabolic disorders.

